WO2023021591A1 - 子宮内膜モデル、子宮内膜モデルの作製方法、及び子宮内膜着床モデル - Google Patents
子宮内膜モデル、子宮内膜モデルの作製方法、及び子宮内膜着床モデル Download PDFInfo
- Publication number
- WO2023021591A1 WO2023021591A1 PCT/JP2021/030100 JP2021030100W WO2023021591A1 WO 2023021591 A1 WO2023021591 A1 WO 2023021591A1 JP 2021030100 W JP2021030100 W JP 2021030100W WO 2023021591 A1 WO2023021591 A1 WO 2023021591A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- medium
- endometrial
- model
- endometrium
- Prior art date
Links
- 230000002357 endometrial effect Effects 0.000 title claims abstract description 112
- 210000004696 endometrium Anatomy 0.000 title claims abstract description 87
- 238000002513 implantation Methods 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 132
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 69
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 51
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 44
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 44
- 210000002308 embryonic cell Anatomy 0.000 claims description 27
- 102000012422 Collagen Type I Human genes 0.000 claims description 25
- 108010022452 Collagen Type I Proteins 0.000 claims description 25
- 210000002220 organoid Anatomy 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 210000000251 trophoblastic cell Anatomy 0.000 claims description 6
- 230000001573 trophoblastic effect Effects 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 8
- 239000002609 medium Substances 0.000 description 160
- 239000000499 gel Substances 0.000 description 46
- 239000003112 inhibitor Substances 0.000 description 36
- 230000035800 maturation Effects 0.000 description 29
- 238000000034 method Methods 0.000 description 26
- 239000007640 basal medium Substances 0.000 description 24
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 19
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 19
- 230000001939 inductive effect Effects 0.000 description 18
- 108010082117 matrigel Proteins 0.000 description 18
- 108010003044 Placental Lactogen Proteins 0.000 description 17
- 239000000381 Placental Lactogen Substances 0.000 description 17
- 239000003446 ligand Substances 0.000 description 17
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 17
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 17
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 16
- 239000000512 collagen gel Substances 0.000 description 16
- 239000011435 rock Substances 0.000 description 15
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 14
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 14
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 14
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 14
- 229940126864 fibroblast growth factor Drugs 0.000 description 14
- 102000003998 progesterone receptors Human genes 0.000 description 14
- 108090000468 progesterone receptors Proteins 0.000 description 14
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 14
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 13
- 101800003838 Epidermal growth factor Proteins 0.000 description 13
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 13
- 229940116977 epidermal growth factor Drugs 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 12
- 108010057464 Prolactin Proteins 0.000 description 12
- 102100024819 Prolactin Human genes 0.000 description 12
- 229940015047 chorionic gonadotropin Drugs 0.000 description 12
- 229940097325 prolactin Drugs 0.000 description 12
- IYOZTVGMEWJPKR-VOMCLLRMSA-N 4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-VOMCLLRMSA-N 0.000 description 11
- 210000002459 blastocyst Anatomy 0.000 description 10
- 210000000981 epithelium Anatomy 0.000 description 10
- 229960005309 estradiol Drugs 0.000 description 10
- 102000015694 estrogen receptors Human genes 0.000 description 10
- 108010038795 estrogen receptors Proteins 0.000 description 10
- QHKYPYXTTXKZST-UHFFFAOYSA-N SB-202190 Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 QHKYPYXTTXKZST-UHFFFAOYSA-N 0.000 description 9
- 210000004102 animal cell Anatomy 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- 229940126560 MAPK inhibitor Drugs 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 8
- 229940095074 cyclic amp Drugs 0.000 description 8
- 229930182833 estradiol Natural products 0.000 description 8
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 8
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 210000005168 endometrial cell Anatomy 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000002993 trophoblast Anatomy 0.000 description 7
- DVKQVRZMKBDMDH-UUOKFMHZSA-N 8-Br-cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DVKQVRZMKBDMDH-UUOKFMHZSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102100035721 Syndecan-1 Human genes 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- -1 etc.) Proteins 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 102000004576 Placental Lactogen Human genes 0.000 description 5
- 239000012574 advanced DMEM Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 239000012583 B-27 Supplement Substances 0.000 description 4
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 239000012580 N-2 Supplement Substances 0.000 description 4
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000012881 co-culture medium Substances 0.000 description 4
- 210000003785 decidua Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 210000005059 placental tissue Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 238000010867 Hoechst staining Methods 0.000 description 3
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000009751 slip forming Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 description 2
- IYOZTVGMEWJPKR-UHFFFAOYSA-N 4-(1-aminoethyl)-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC(C(N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- BGIYKDUASORTBB-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 BGIYKDUASORTBB-UHFFFAOYSA-N 0.000 description 2
- FYSRKRZDBHOFAY-UHFFFAOYSA-N 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)-3-pyridinecarboxamide Chemical compound FC=1C=CC=C(F)C=1N(C(=O)N)C(N=1)=CC=C(C(N)=O)C=1C1=CC=C(F)C=C1F FYSRKRZDBHOFAY-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108091007911 GSKs Proteins 0.000 description 2
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 2
- PQCXVIPXISBFPN-UHFFFAOYSA-N SB 415286 Chemical compound C1=C(Cl)C(O)=CC=C1NC1=C(C=2C(=CC=CC=2)[N+]([O-])=O)C(=O)NC1=O PQCXVIPXISBFPN-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 102000046645 human LIF Human genes 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002346 layers by function Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NTSBZVCEIVPKBJ-UHFFFAOYSA-N 1-azakenpaullone Chemical compound C1C(=O)NC2=CC=CN=C2C2=C1C1=CC(Br)=CC=C1N2 NTSBZVCEIVPKBJ-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- ZRHRPGSSSVYBRG-UHFFFAOYSA-N 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole Chemical compound IC1=CC=CC(CSC=2OC(=NN=2)C=2C=CN=CC=2)=C1 ZRHRPGSSSVYBRG-UHFFFAOYSA-N 0.000 description 1
- KYVDGDMQERQKOY-UHFFFAOYSA-N 2-chloro-1-(4,5-dibromo-2-thiophenyl)ethanone Chemical compound ClCC(=O)C1=CC(Br)=C(Br)S1 KYVDGDMQERQKOY-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- WGWCZBLPEQPEGF-UHFFFAOYSA-N C1(C=CC=C1)[Ru].C1=CC=NC=2C=CC=3C=4C=CC=CC4NC3C21 Chemical compound C1(C=CC=C1)[Ru].C1=CC=NC=2C=CC=3C=4C=CC=CC4NC3C21 WGWCZBLPEQPEGF-UHFFFAOYSA-N 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102100039244 ETS-related transcription factor Elf-5 Human genes 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- JYCUVOXSZBECAY-UHFFFAOYSA-N GSK3-XIII Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C=2C=CC=CC=2)=N1 JYCUVOXSZBECAY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 101000813141 Homo sapiens ETS-related transcription factor Elf-5 Proteins 0.000 description 1
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 101000757378 Homo sapiens Transcription factor AP-2-alpha Proteins 0.000 description 1
- 101000802329 Homo sapiens Zinc finger protein 750 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150097713 SCD1 gene Proteins 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000003705 Syndecan-1 Human genes 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 102100022972 Transcription factor AP-2-alpha Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100034644 Zinc finger protein 750 Human genes 0.000 description 1
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004952 blastocoel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108700041430 link Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037211 monthly cycles Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- JYYLVUFNAHSSFE-UHFFFAOYSA-N pamapimod Chemical compound O=C1N(C)C2=NC(NC(CCO)CCO)=NC=C2C=C1OC1=CC=C(F)C=C1F JYYLVUFNAHSSFE-UHFFFAOYSA-N 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000002299 prolactin secreting cell Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 1
- VHTMKTNUXDACHB-KHXPSBENSA-M sodium;9-[(4ar,6r,7r,7ar)-7-methoxy-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-8-(4-chlorophenyl)sulfanylpurin-6-amine Chemical compound [Na+].N=1C2=C(N)N=CN=C2N([C@@H]2O[C@@H]3COP([O-])(=O)O[C@H]3[C@H]2OC)C=1SC1=CC=C(Cl)C=C1 VHTMKTNUXDACHB-KHXPSBENSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
- G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
- G09B23/30—Anatomical models
- G09B23/34—Anatomical models with removable parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Definitions
- the present invention relates to an endometrium model, an endometrium model preparation method, and an endometrium implantation model.
- the endometrium is an epithelial tissue that exists in the uterus and is a tissue necessary for the establishment of pregnancy.
- the functional layer of the endometrium undergoes monthly cycles of regeneration, differentiation, and shedding.
- the functional layer of the endometrium proliferates in an estrogen-dependent manner, regenerates the mucosa, and differentiates into a progesterone-dominant secretory phase.
- the supraciliary luminal epithelium is implanted with a fertilized egg, providing the microenvironment essential for placentation.
- Non-Patent Document 1 has a simple spherical structure, and is different from the endometrial structure of a living body in terms of spatial morphology. Also, embryo implantation cannot be simulated because the apical surface that receives the embryo is internal to the structure.
- the present invention provides an endometrium model in which the apical surface of endometrial epithelial cells is exposed, a method for producing the endometrium model, and an endometrium implantation model using the endometrium model.
- the challenge is to
- the present invention includes the following aspects.
- An endometrial model wherein at least a portion of the exposed endometrial epithelial cells form a continuous luminal and non-luminal structure.
- [4] The endometrium model according to any one of [1] to [3], wherein part of the endometrial epithelial cells are present inside the gel.
- [5] (a) a step of allowing endometrial epithelial cells to exist inside a gel containing a stromal extracellular matrix; and (b) a step of culturing the endometrial epithelial cells after step (a).
- a method for producing an endometrium model comprising: [6] The method for producing an endometrium model according to [4], wherein the stromal extracellular matrix is type I collagen.
- An endometrial implantation model comprising the endometrial model of any one of [1] to [4] and an embryonic cell.
- an endometrium model in which the apical surface of endometrial epithelial cells is exposed a method for producing the endometrium model, and an endometrium implantation model using the endometrium model are provided.
- FIG. 1 is a schematic diagram showing an example of an endometrial implantation model
- FIG. 2 shows bright-field phase-contrast microscopy images of endometrial models made using Matrigel or type I collagen gels. Immunostaining images of an endometrium model prepared using Matrigel or type I collagen gel are shown.
- FIG. 4 shows an immunostained image of an endometrium model prepared using type I collagen gel.
- FIG. Images of endometrial epithelial cells plated with Matrigel or type I collagen gel are shown.
- 1 shows an endometrium implantation model produced by co-culturing an endometrium model produced using type I collagen gel and a blastocyst-like structure derived from ES cells.
- 1 shows an endometrium implantation model produced by co-culturing an endometrium model produced using type I collagen gel and a blastocyst-like structure derived from TS cells.
- the top image is a merged fluorescence microscope image that detected GFP, OCT4, SCD1, F-actin, and Hoechast. Merged in the lower image is an enlarged view of the boxed portion of the upper image.
- GFP (TSC) in the lower image is a fluorescence microscope image in which GFP in the boxed portion of the upper image was detected.
- SDC1 in the lower image is a fluorescence microscope image in which SDC1 in the squared portion of the upper image was detected.
- the term “comprise” means that it may include elements other than the subject element.
- the term “consist of” means containing no elements other than the subject element.
- the term “consisting essentially of” means that it does not include constituent elements other than the subject constituent elements in a mode that exhibits a special function (such as a mode that completely loses the effect of the invention). means.
- the word “comprise” includes aspects that "consist of” and aspects that "consist essentially of.”
- the "cells” described herein can be isolated. “Isolated” means separated from the natural state. A "cell” as described herein can be an isolated cell.
- Endometrial model A first aspect of the present disclosure is an endometrial model.
- the endometrial model comprises a gel comprising a stromal extracellular matrix and endometrial epithelial cells.
- at least a portion of said endometrial epithelial cells are exposed on the surface of said gel.
- at least a portion of the endometrial epithelial cells exposed on the surface of the gel form a series of luminal and non-luminal structures.
- FIG. 1 is a schematic diagram showing an endometrium model of one embodiment.
- the endometrium model 1 includes a gel 20 containing a stromal extracellular matrix and cell aggregates (10a, 10b) of endometrial epithelial cells.
- the cell aggregates 10a are cell aggregates of endometrial epithelial cells exposed on the surface of the gel 20 containing the stromal extracellular matrix.
- the cell aggregate 10b is a cell aggregate of endometrial epithelial cells present inside the gel 20 containing the stromal extracellular matrix.
- the cell aggregate 10a is exposed on the surface of the gel 20 containing the interstitial extracellular matrix, and has a structure in which a luminal structure 11 and a non-luminal structure 12 are continuously formed.
- a “luminal structure” refers to a structure in which endometrial epithelial cells are invaginated on the side of the gel 20 containing the interstitial extracellular matrix.
- a “non-luminal structure” refers to a structure that is not a luminal structure. Examples of non-luminal structures include, for example, flattened membranous structures.
- a structure "in which a luminal structure and a non-luminal structure are continuously formed" includes at least one luminal structure and at least one non-luminal structure, and the luminal structure and the non-luminal structure are connected.
- the number of luminal structures 11 possessed by the cell aggregate 10a is not particularly limited. Depending on the size of the cell aggregate 10a, the cell aggregate 10a can have multiple luminal structures 11. FIG. When the cell aggregate 10a has a plurality of luminal structures 11, two luminal structures 11 are connected by a non-luminal structure 12. As shown in FIG.
- the endometrial epithelial cells that make up the luminal structure 11 may express progesterone receptor (PGR).
- PGR progesterone receptor
- the luminal structure 11 may have functions similar to mature endometrial glandular epithelium.
- the gel 20 containing the stromal extracellular matrix contains the stromal extracellular matrix.
- a "stromal extracellular matrix” is an extracellular matrix that is predominantly present in the stroma.
- stromal extracellular matrices include type I collagen, proteoglycans (versican, decorin, etc.), fibronectin, and the like. Among them, type I collagen is preferable as the stromal extracellular matrix.
- the stromal extracellular matrix contained in the gel 20 containing the stromal extracellular matrix may be one type or two or more types.
- the gel 20 containing the stromal extracellular matrix may contain other extracellular matrices in addition to the stromal extracellular matrix.
- extracellular matrices include basement membrane extracellular matrices such as laminin, type IV collagen, heparan sulfate proteoglycan, and entactin; cartilage extracellular matrices such as hyaluronic acid, type II collagen, and link proteins. .
- commercially available products such as Matrigel (registered trademark) may be used.
- the other extracellular matrices may be of one type or two or more types.
- the gel 20 containing the stromal extracellular matrix is 50% by volume or more, 55% by volume or more, 60% by volume or more, 65% by volume or more, 70% by volume or more, 75% by volume or more, or 80% by volume, based on the total gel volume. It preferably contains stromal extracellular matrix gel at vol % or more. The gel 20 containing the stromal extracellular matrix may be 100% by volume of the stromal extracellular matrix gel.
- the endometrium model 1 can be maintained in culture medium or the like.
- the medium is not particularly limited as long as it is a medium capable of maintaining the endometrium model 1.
- Examples of the medium include a medium obtained by adding a growth factor, a ROCK inhibitor, a GSK3 ⁇ inhibitor, a p38 MAPK inhibitor, a maturation inducer, etc. to a basal medium generally used for culturing animal cells.
- basal media examples include Doulbecco's modified Eagle's Medium (DMEM) medium, DMEM/F12 medium, Advanced DMEM/F12 medium, IMDM medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM) medium, ⁇ MEM medium, Examples include Ham's F12 medium, RPMI1640 medium, Fischer's medium, and mixed media thereof.
- DMEM/F12 Doulbecco's modified Eagle's Medium
- DMEM/F12 medium examples include Ham's F12 medium, RPMI1640 medium, Fischer's medium, and mixed media thereof.
- Preferred basal media include, for example, DMEM/F12.
- the basal medium may contain serum (such as fetal bovine serum (FBS)) and/or serum substitutes, if necessary.
- Serum replacements include, for example, albumin, transferrin, sodium selenite, ITS-X (Invitrogen), knockout serum replacement (KSR), N2 supplement (Invitrogen), B27 supplement (Invitrogen), fatty acids, Insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3′-thiolglycerol, etc.
- the basal medium optionally contains lipids, amino acids, L-glutamine, Glutamax, non-essential amino acids, vitamins, growth It may contain components such as factors, antibiotics, antioxidants, pyruvic acid, buffers, inorganic salts, etc. These can be used in combination as appropriate.
- basal medium for example, bovine serum albumin (BSA), ITS-X, L-ascorbic acid, and antibiotics (penicillin, streptomycin, etc.) are added to the above basal medium (eg, DMEM/F12). media.
- BSA bovine serum albumin
- ITS-X ITS-X
- L-ascorbic acid ITS-X
- antibiotics penicillin, streptomycin, etc.
- TS basal medium used in Examples described later.
- growth factors include, but are not limited to, epidermal growth factor (EGF), fibroblast growth factor (FGF), bone morphogenic protein (BMP), and the like. .
- EGF epidermal growth factor
- FGF fibroblast growth factor
- BMP bone morphogenic protein
- EGF binds to the EGF receptor (EGFR) present on the cell surface, induces EGF signaling, and acts as a mitogenic factor.
- the organism from which EGF is derived is not particularly limited, but human EGF is preferred.
- Human FGF may be recombinant produced by non-human cells.
- a commercially available EGF can be used.
- the concentration of EGF in the medium is not particularly limited, but can be, for example, 5-200 ng/mL.
- the concentration of EGF in the medium is preferably 10-150 ng/mL, more preferably 10-100 ng/mL, even more preferably 10-80 ng/mL, and particularly preferably 10-60 ng/mL.
- FGF has a high affinity for heparan sulfate proteoglycans, forms a complex with heparan sulfate proteoglycans and the FGF receptor (FGFR) on the cell surface, induces FGF signaling, and acts as a mitogenic factor.
- the organism from which FGF is derived is not particularly limited, but human FGF is preferred. Human FGF may be recombinant produced by non-human cells.
- FGF2 also referred to as bFGF
- a commercially available FGF can be used.
- the concentration of FGF (eg, FGF2) in the medium is not particularly limited, but can be, for example, 5-200 ng/mL.
- the concentration of FGF (eg, FGF2) in the medium is preferably 10-150 ng/mL, more preferably 20-100 ng/mL, still more preferably 30-80 ng/mL, and particularly preferably 40-60 ng/mL.
- the medium may contain heparin.
- Heparin has the effect of promoting the activity of FGF.
- Heparin is preferably in the form of a salt.
- heparin salts include salts with alkali metals such as lithium, sodium and potassium; salts with alkaline earth metals such as calcium, barium and magnesium; salts with metals such as aluminum, zinc, copper and iron; ammonium salts; salts with organic bases; and salts with amino acids.
- Commercially available heparin can be used.
- the concentration of heparin in the medium is not particularly limited, but can be, for example, 0.001-10 ⁇ g/mL.
- BMP is a protein belonging to the transforming growth factor ⁇ (TGF ⁇ ) superfamily, and controls cell death induction, cell differentiation, and the like.
- Organisms from which BMPs are derived are not particularly limited, but human BMPs are preferred. Human BMPs may be recombinant produced by non-human cells.
- BMP4 is preferred as the BMP.
- a commercially available BMP can be used.
- the concentration of BMP (eg, BMP4) in the medium is not particularly limited, but can be, for example, 5-200 ng/mL.
- the concentration of BMP (eg, BMP4) in the medium is preferably 10-150 ng/mL, more preferably 20-100 ng/mL, even more preferably 30-80 ng/mL, and particularly preferably 40-60 ng/mL.
- ROCK (Rho-associated coiled-coil containing protein kinase) inhibitor is a substance that inhibits the function of Rho-associated kinase.
- ROCK inhibitors include trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 1-(5-isoquinolinylsulfonyl)homopiperazine (1-(5-Isoquinolinylsulfonyl ) homopiperazine), or salts thereof.
- ROCK inhibitors may be antisense nucleic acids against ROCK, siRNA, dominant negative mutants, expression vectors thereof, and the like.
- Commercial products of trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide or a salt thereof include Y27632 ((R)-(+)-trans-N-(4-pyridyl)- 4-(1-aminoethyl)-cyclohexanecarboxamide.2HCl.H 2 O) and the like.
- ROCK inhibitors may be used singly or in combination of two or more.
- Y27632 is preferably used as the ROCK inhibitor.
- the concentration of the ROCK inhibitor in the medium is not particularly limited, but can be, for example, 0.1-50 ⁇ M, preferably 1-20 ⁇ M, more preferably 1-15 ⁇ M, and even more preferably 3-12 ⁇ M.
- a GSK (Glycogen Synthase Kinase) 3 ⁇ inhibitor is a substance that inhibits the function of GSK3 ⁇ , such as kinase activity (eg, ability to phosphorylate ⁇ -catenin).
- GSK3 ⁇ inhibitors include, for example, 6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl] Amino]nicotinonitrile, Kenpaullone, 1-Azakenpaullone, CHIR98014, AR-A014418, CT99021, CT20026, SB216763, AR-A014418, Lithium, SB415286, TDZD-8, BIO, BIO-acetoxime, (5 -methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine, pyridocarbazole-cyclopentadienylruthenium complex, TDZD-8 4-benzyl-2-methyl- 1,2,4-thiadiazolidine-3,5-dione, 2-thio(3-iodobenzyl)-5-(1-pyridyl
- GSK3 ⁇ inhibitors may be antisense nucleic acids, siRNAs, dominant negative mutants against GSK3 ⁇ , expression vectors thereof, etc. 6-[[2-[[4 Commercially available products of -(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]nicotinonitrile include CHIR99021. GSK3 ⁇ inhibitors may be used singly or in combination of two or more. CHIR99021 is preferably used as the GSK3 ⁇ inhibitor.
- the concentration of the GSK3 ⁇ inhibitor in the medium is not particularly limited, but can be, for example, 0.1-20 ⁇ M, preferably 0.2-10 ⁇ M, more preferably 0.5-5 ⁇ M, and 0.5-3 ⁇ M is more preferred.
- a p38 MAPK inhibitor is a substance that inhibits the function of p38 MAPK (P38 mitogen-activated protein kinase).
- Examples of p38 MAPK inhibitors include SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole), SB203580 (4-[4-( 4-fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl]pyridine), VX702 (6-(N-carbamoyl-2,6-difluoroanilino)-2-( 2,4-difluorophenyl)pyridine-3-carboxamide), VX745 (5-(2,6-dichlorophenyl)-2-[2,4-difluorophenyl)thio]-6H-pyrimido[1,6-b] pyri
- a maturation inducer is a factor that induces maturation of endometrial cells.
- the maturation-inducing factor is not particularly limited as long as it can induce maturation of endometrial cells.
- Maturation inducers include, for example, estrogen receptor ligands, progesterone receptor ligands, cyclic AMP (cAMP) or derivatives thereof, prolactin, placental lactogen, chorionic gonadotropin and the like.
- Estrogen receptor ligands are substances that bind to the estrogen receptor. Examples of estrogen receptor ligands include estrone, estradiol, estriol and the like. Examples of estradiol include ⁇ -estradiol, 17 ⁇ -estradiol and the like. Estrogen receptor ligands may be used singly or in combination of two or more. Estrogen receptor ligand is preferably estradiol. The concentration of the estrogen receptor ligand in the medium is not particularly limited. .
- a progesterone receptor ligand is a substance that binds to the progesterone receptor.
- Progesterone receptor ligands include progesterone, medroxyprogesterone acetate and the like. Progesterone receptor ligands may be used singly or in combination of two or more. Medroxyprogesterone acetate is preferably used as the progesterone receptor ligand.
- the concentration of progesterone or a derivative thereof in the medium is not particularly limited, but can be, for example, 0.1 to 20 ⁇ M, preferably 0.2 to 10 ⁇ M, more preferably 0.5 to 5 ⁇ M, and 0.5 to 3 ⁇ M is even more preferred.
- cAMP or derivatives thereof include 8-bromoadenosine-3′-5′-cyclic monophosphate (8-Br-cAMP), dibutyryl-cAMP, 8-CPT-2-Me-cAMP sodium salt (8-(4 -Chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate sodium salt) and the like.
- 8-Br-cAMP is preferably used as cAMP or a derivative thereof.
- the concentration of cAMP or a derivative thereof in the medium is not particularly limited, but can be, for example, 0.1 to 200 ⁇ M, preferably 1 to 150 ⁇ M, more preferably 10 to 100 ⁇ M, and even more preferably 20 to 80 ⁇ M.
- Prolactin is a hormone secreted from prolactin-secreting cells in the anterior pituitary gland.
- the organism from which prolactin is derived is not particularly limited, but human prolactin is preferred.
- Human prolactin may be recombinant produced by non-human cells.
- Commercially available prolactin can be used.
- the concentration of prolactin in the medium is not particularly limited, but can be, for example, 5-200 ng/mL.
- the concentration of prolactin in the medium is preferably 10-150 ng/mL, more preferably 10-100 ng/mL, even more preferably 10-80 ng/mL, and particularly preferably 10-60 ng/mL.
- Placental lactogen is a peptide hormone secreted from the placenta.
- the organism from which the placental lactogen is derived is not particularly limited, but human placental lactogen is preferred.
- the human placental lactogen may be recombinant produced by non-human cells.
- a commercially available placental lactogen can be used.
- the concentration of placental lactogen in the medium is not particularly limited, but can be, for example, 5-200 ng/mL.
- the concentration of the placental lactogen in the medium is preferably 10-150 ng/mL, more preferably 10-100 ng/mL, even more preferably 10-80 ng/mL, and particularly preferably 10-60 ng/mL.
- Chorionic gonadotropin is a peptide hormone secreted from the trophoblast syncytium.
- the organism from which chorionic gonadotropin is derived is not particularly limited, but human chorionic gonadotropin is preferred.
- the human chorionic gonadotropin may be recombinant produced by non-human cells.
- a commercially available chorionic gonadotropin can be used.
- the concentration of chorionic gonadotropin in the medium is not particularly limited, but can be, for example, 0.01-100 ⁇ g/mL.
- the concentration of chorionic gonadotropin in the medium is preferably 0.05 to 50 ⁇ g/mL, more preferably 0.1 to 20 ⁇ g/mL, still more preferably 0.2 to 10 ⁇ g/mL, and 0.5 to 5 ⁇ g/mL. Especially preferred.
- a basal medium for animal cells e.g., TS basal medium, etc.
- a growth factor EGF, etc.
- a ROCK inhibitor Y27632, etc.
- a GSK3 ⁇ inhibitor CHR99021, etc.
- media supplemented with p38 MAPK inhibitors SB202190, etc.
- ECSY medium used in Examples described later.
- further maturation-inducing factors prolactin, placental lactogen, chorionic gonadotropin, etc.
- growth factors EGF, etc.
- ROCK inhibitors Y27632, etc.
- GSK3 ⁇ inhibitors CHR99021, etc.
- p38 MAPK inhibitors SB202190, etc.
- a basal medium for animal cells e.g., TS basal medium, etc.
- maturation-inducing factors estradiol, medroxyprogesterone acetate, 8-Br-cAMP, prolactin, placental lactogen, chorionic gonadotropin, etc.
- maturation-inducing factors estradiol, medroxyprogesterone acetate, 8-Br-cAMP, prolactin, placental lactogen, chorionic gonadotropin, etc.
- Specific examples of such a medium include, for example, ECSY+EPC medium used in the Examples described later, human prolactin (e.g., 20 ng/mL), human placental lactogen (e.g., 20 ng/mL), human chorionic gonadotropin ( 1 ⁇ g/mL) (eg, ECSY+EPC+PLG medium).
- the endometrium model of this embodiment has a structure in which endometrial epithelial cells are exposed on the gel surface. Furthermore, it has a luminal structure similar to the endometrial glandular epithelium. These structural features resemble the endometrium in vivo. Therefore, the endometrium model of this embodiment can be applied to drug screening and drug evaluation for diseases related to the endometrium (endometriosis, endometrial cancer, etc.). Also, since the apical surface of the endometrial epithelial cells is exposed, it is possible to simulate implantation. Therefore, it can be applied to elucidation of the mechanism of implantation or implantation failure, screening of therapeutic agents for implantation failure, and evaluation of therapeutic agents for implantation failure.
- a second aspect of the present disclosure is a method of creating an endometrium model.
- the method according to this aspect comprises the steps of (a) allowing endometrial epithelial cells to exist inside a gel containing a stromal extracellular matrix; and (b) culturing the endometrial epithelial cells. include.
- step (a)> endometrial epithelial cells are present inside a gel containing a stromal extracellular matrix.
- Endometrial epithelial cells may be isolated from endometrial epithelial tissue, or cultures of endometrial epithelial cells may be used.
- a known method can be used to isolate endometrial epithelial tissue from endometrial tissue.
- Decidua may be used as the endometrial epithelial tissue.
- Endometrial epithelial cells can be isolated, for example, by separating the cells, using mechanical and/or enzymatic treatments as appropriate on the endometrial epithelial tissue. Mechanical treatments include cutting with a scalpel.
- the enzymatic treatment includes treatment with a protease (eg, dispase, collagenase, etc.) having extracellular matrix degrading activity.
- the endometrial epithelial cells can be collected using a strainer, filter, or the like.
- the collected endometrial epithelial cells may be appropriately washed with a medium or the like.
- the gel containing the interstitial extracellular matrix can be the same one as described above.
- a gel containing a stromal extracellular matrix preferably contains type I collagen as the stromal extracellular matrix.
- the method for allowing endometrial epithelial cells to exist inside the gel containing the stromal extracellular matrix is not particularly limited.
- cells may be collected from a culture solution of endometrial epithelial cells by centrifugation or the like, and mixed with a gel containing a stromal extracellular matrix.
- endometrial epithelial cells may be suspended in an appropriate medium to prepare a cell suspension, and the cell suspension may be injected into a gel containing a stromal extracellular matrix.
- the number of endometrial epithelial cells to be seeded on the gel containing the stromal extracellular matrix is not particularly limited.
- the number of seeded cells is, for example, 1 or more, 10 or more, 10 2 or more, 10 3 or more, 10 4 or more, 10 5 or more, 10 6 or more, 10 7 or more, 10 8 or more. , 10 9 or more, or 10 10 or more.
- the upper limit of the number of seeded cells is not particularly limited. Examples include 10 20 or less, 10 15 or less, 10 14 or less, 10 13 or less, or 10 12 or less. The lower limit value and the upper limit value can be appropriately combined.
- step (b) In step (b), the endometrial epithelial cells are cultured after step (a).
- Cultivation may be performed by adding an appropriate medium to a gel containing a stromal extracellular matrix containing endometrial epithelial cells.
- culture vessels include, but are not limited to, untreated well plates, untreated dishes, and the like.
- the culture medium those listed above can be used. It is preferable to replace the medium appropriately during the culture.
- the frequency of medium replacement is not particularly limited, but includes, for example, 2 to 3 times a week.
- a maturation-inducing factor may be added to the medium as appropriate to promote the maturation of endometrial epithelial cells. For example, at the initial stage of culture, culture may be performed in a medium containing no maturation-inducing factor. Subsequently, the medium may be replaced with a maturation-inducing factor-containing medium and further cultured.
- the culture period in a maturation factor-free medium is, for example, 1 day or longer, 2 days or longer, 3 days or longer, 4 days or longer, 5 days or longer, 6 days or longer, or 7 days or longer. is mentioned.
- the upper limit of the culture period in a maturation factor-free medium is not particularly limited, but for example, 30 days or less, 25 days or less, 20 days or less, 15 days or less, 12 days or less, or 10 days. Examples include the following.
- the lower limit value and the upper limit value can be appropriately combined.
- the culture period in a maturation factor-containing medium is, for example, 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, or 7 days or more. mentioned.
- the upper limit of the culture period in a maturation factor-containing medium is not particularly limited, but for example, 30 days or less, 25 days or less, 20 days or less, 15 days or less, 12 days or less, 10 days or less is mentioned.
- the lower limit value and the upper limit value can be appropriately combined.
- the maturation-inducing factor is selected from the group consisting of estrogen receptor ligands, progesterone receptor ligands, cAMP or derivatives thereof, prolactin, placental lactogen, and chorionic gonadotropin.
- a medium containing 3 or more, 4 or more, or 5 or more maturation-inducing additive factors may be used.
- a medium containing all of estrogen receptor ligand, progesterone receptor ligand, cAMP or derivatives thereof, prolactin, placental lactogen, and chorionic gonadotropin eg, ECSY+EPC+PLG medium
- ECSY+EPC+PLG medium ECSY+EPC+PLG medium
- the endometrial epithelial cells inside the gel containing the stromal extracellular matrix migrate within the gel, and some cells reach the gel surface. Cells reaching the gel surface form a continuous structure of luminal and non-luminal structures on the gel surface. Culturing in the maturation-inducing factor-containing medium can be continued until the endometrial epithelial cells form the structure.
- the culture conditions can be those generally used for culturing animal cells.
- the culture temperature can be 32-40° C. (preferably 35-38° C., typically 37° C.) and the CO 2 concentration can be 2-5% (preferably 5%).
- the endometrium model according to the first aspect can be produced.
- a third aspect of the present disclosure is an endometrial implantation model.
- the endometrial implantation model according to this aspect includes the endometrial model according to the first aspect and an embryonic cell.
- FIG. 2 is a schematic diagram showing an endometrial implantation model of one embodiment.
- Endometrial implantation model 2 includes endometrial model 1 and embryonic cells 30 .
- Embryonic cells 30 may or may not be implanted on the apical surface of the endometrium model 1 .
- Embryonic cells refer to cells that can simulate implantation into the endometrium.
- a fertilized egg travels through the fallopian tube and reaches the uterus.
- a fertilized egg cleaves while moving through the fallopian tube, and becomes a blastocyst through a 2-cell stage embryo, a 4-cell stage embryo, an 8-cell stage embryo, and a morula.
- the blastocyst reaches the uterus, it becomes an expanded blastocyst, the zona pellucida becomes thin, and the zona pellucida breaks to become a post-hatching blastocyst. After hatching, the blastocyst settles against the endometrium.
- a blastocyst is composed of an inner cell mass, a blastocyst cavity, and a trophoblast, and trophoblast cells invade the endometrium to establish implantation.
- Embryonic cells are typically cells that constitute an embryo, and may be any of fertilized eggs, 2-cell stage embryos, 4-cell stage embryos, 8-cell stage embryos, morulae, and blastocysts. .
- the embryonic cell may be a cell isolated from an embryo as described above or a cell derived from said isolated cell.
- Embryonic cells may be pluripotent stem cells or cells derived from pluripotent stem cells.
- Embryonic cells may be cells isolated from the placenta or cells derived from said cells.
- Embryonic cells include, for example, trophoblastic stem cells, cytotrophoblastic cells, extravillous trophoblastic cells, syncytial trophoblastic cells, pluripotent stem cells, and cells derived from these.
- Trophoblast stem cells may be derived from blastocysts, may be derived from cytotrophoblast cells (CT cells), It may also be derived from a potential stem cell. Induction of TS cells from blastocysts can be performed by known methods. For example, mechanical and/or enzymatic treatments are optionally used on placental tissue to separate cells. Then, after culturing the cells in a medium that induces TS cells, TS cells are established using the expression of TS cell markers (GATA2-positive, GATA3-positive, TFAP2-positive, ELF5-positive, ZNF750-positive, CDX2-negative, etc.) as indicators. can be done.
- TS cell markers GATA2-positive, GATA3-positive, TFAP2-positive, ELF5-positive, ZNF750-positive, CDX2-negative, etc.
- a method for inducing TS cells from CT cells for example, the method described in Japanese Patent No. 6400832 can be used.
- a method for inducing TS cells from pluripotent stem cells for example, the method described in International Publication No. 2020/250438 and the like can be used.
- CT cells isolated from the placenta can be used. Isolation of CT cells from the placenta can be achieved, for example, by appropriately using mechanical and/or enzymatic treatments on the placental tissue to separate the cells and determine the expression of CT cell markers (CD49f-positive, E-cadherin-positive, etc.). As an indicator, CT cells can be isolated (Patent No. 6400832, Haider, S., et al., Stem Cell Reports 11, 537-551 (2016).)
- Syncytiotrophoblast cells may be isolated from the placenta or may be derived from TS cells. Isolation of ST cells from the placenta is, for example, using mechanical and/or enzymatic treatments on the placental tissue as appropriate to separate the cells and detect ST cell markers (Syndecan 1 (SDC1) positive, human chorionic gonadotropin (hCG ) positive, etc.) can be used as an index to isolate ST cells.
- ST cell markers Syndecan 1 (SDC1) positive, human chorionic gonadotropin (hCG ) positive, etc.
- Methods for inducing ST cells from TS cells include, for example, the methods described in International Publication No. 2020/250438 and the like.
- Extravillous trophoblast cells may be isolated from placenta or may be derived from TS cells. Isolation of EVT cells from the placenta can be achieved, for example, by appropriately using mechanical and/or enzymatic treatment on the placental tissue to separate the cells, and using the expression of an EVT cell marker (such as HLA-G positive) as an index, EVT cells can be isolated. Methods for inducing EVT cells from TS cells include, for example, the methods described in International Publication No. 2020/250438.
- Pluripotent stem cells are cells having pluripotency, and may be embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS cells). It may also be a cell having pluripotency induced from these stem cells.
- a method for producing pluripotent stem cells is not particularly limited, and known methods can be used.
- Cell lines of ES cells and iPS cells are also available from cell banks such as the RIKEN BioResource Research Center (RIKEN BRC).
- Pluripotent stem cells are preferably ES cells or iPS cells, more preferably ES cells.
- Embryonic cells may form spheroids or organoids. Formation of spheroids or organoids from embryonic cells can be performed by known methods. For example, using a medium as described above (for example, a medium supplemented with a growth factor, a ROCK inhibitor, a GSK ⁇ inhibitor, and a p38 MAPK inhibitor in a basal medium), the embryo cells are cultured in suspension to obtain Spheroids or organoids can be produced.
- a medium as described above for example, a medium supplemented with a growth factor, a ROCK inhibitor, a GSK ⁇ inhibitor, and a p38 MAPK inhibitor in a basal medium
- the embryonic cell spheroids or organoids may be cell aggregates derived from TS cells.
- cell aggregates can be induced by suspension culture of TS cells in TS medium (Okae et al Cell Stem Cell 2018).
- the cell aggregate may contain one or more cells selected from the group consisting of TS cells, CT cells, ST cells, and EVT cells, and the group consisting of TS cells, CT cells, and ST cells. It may contain one or more selected cells.
- the spheroids or organoids of embryonic cells may be blastocyst-like structures.
- a blastocyst-like structure is a cell structure having a structure similar to that of a blastocyst derived from cells with pluripotency such as pluripotent stem cells.
- Blastocyst-like structures can be induced by known methods (eg, Yu L, et al., Nature. 2021 Mar;591(7851):620-626.).
- blastocyst-like structures can be obtained by culturing pluripotent stem cells using 5i/L/A medium, then HDM medium, and then TDM medium.
- Naive type pluripotent stem cells may be used or primed type pluripotent stem cells may be used, but naive type pluripotent stem cells are preferably used.
- An endometrial implantation model can be produced by co-culturing an endometrium model and embryonic cells.
- the medium used for co-cultivation is not particularly limited, but in addition to the above-mentioned medium, IVC1 medium, IVC2 medium, etc. used in Examples can be mentioned.
- a basal medium for animal cells for example, TS basal medium
- a growth factor for example, TS basal medium
- a ROCK inhibitor for example, Y27632, etc.
- a GSK3 ⁇ inhibitor for example, a GSK3 ⁇ inhibitor
- p38 MAPK Inhibitors SB202190 etc.
- maturation-inducing factors estradiol, medroxyprogesterone acetate, 8-Br-cAMP etc.
- a medium supplemented with a maturation-inducing factor such as prolactin, placental lactogen, or chorionic gonadotropin may be used as the co-culture medium.
- a maturation-inducing factor such as prolactin, placental lactogen, or chorionic gonadotropin
- growth factors EGF, etc.
- ROCK inhibitors Y27632, etc.
- GSK3 ⁇ inhibitors CHIR99021, etc.
- p38 MAPK inhibitors SB202190, etc.
- a basal medium for animal cells e.g., TS basal medium, etc.
- maturation-inducing factors estradiol, medroxyprogesterone acetate, 8-Br-cAMP, prolactin, placental lactogen, chorionic gonadotropin, etc.
- maturation-inducing factors eg, ECSY+EPC+PLG medium.
- the co-culture medium includes a basal medium for animal cells (e.g., DMEM/F12 medium, Advanced DMEM/F12 medium, etc.), serum (FBS, etc.), serum substitutes (ITS-X, KSR, etc.), A medium containing amino acids (L-glutamine, N-acetyl-L-cysteine, etc.), organic acids (pyruvic acid, lactic acid, etc.), maturation inducers (estrogen receptor ligands, progesterone receptor ligands, etc.), etc. (for example, IVC1 medium, IVC2 medium, etc.).
- a basal medium for animal cells e.g., DMEM/F12 medium, Advanced DMEM/F12 medium, etc.
- serum FBS, etc.
- serum substitutes ITS-X, KSR, etc.
- a medium containing amino acids L-glutamine, N-acetyl-L-cysteine, etc.
- organic acids pyruvic acid, lactic
- co-cultivation may be performed in IVC1 medium for a predetermined period from the start of co-culture (e.g., half to three days, half to two days, or half to one day), and then co-cultured in IVC2 medium. .
- the culture conditions can be those generally used for culturing animal cells.
- a culture temperature of 32-40° C. (preferably 35-38° C., typically 37° C.) and a CO 2 concentration of 2-5% (preferably 5%) can be used.
- the embryonic cell spheroids or organoids When embryonic cell spheroids or organoids are co-cultured with an endometrium model, the embryonic cell spheroids or organoids can be implanted on the apical surface of the endometrium model. In the implanted spheroids or organoids, the cells at the implantation site may be differentiated into SDC1-positive cells (eg, ST cells).
- SDC1-positive cells eg, ST cells
- the endometrium implantation model according to this aspect includes the endometrium model of the first aspect and embryonic cells, and therefore can simulate implantation into the endometrium. Therefore, the endometrial implantation model according to this aspect can be applied to elucidation of the mechanism of implantation or implantation failure, screening of drugs for implantation failure, and the like.
- TS basal medium A TS basal medium was prepared by adding the following components to DMEM/F12 medium (FUJIFILM Wako). The concentrations given below are the final concentrations of each component in TS basal medium.
- Bovine serum albumin (BSA) (FUJIFILM Wako) 0.15% Penicillin 5,000 units/mL Streptomycin (Thermo Fisher Scientific) 5,000 ⁇ g/mL ITS-X (FUJI FILM Wako) 1% KSR (Thermo Fisher Scientific) 1% L-ascorbic acid (FUJIFILM Wako) 0.2mM
- ECSY medium ECSY medium was prepared by adding the following additive factors to TS basal medium. The concentrations given below are the final concentrations in ECSY medium.
- ECSY + EPC medium ECSY+EPC medium was prepared by adding the following maturation-inducing additive factors to ECSY medium. The concentrations given below are the final concentrations in ECSY+EPC medium.
- ECSY + EPC + PLG medium An ECSY+EPC+PLG medium was prepared by adding the following maturation-inducing additive factors to the ECSY+EPC medium. Concentrations shown below are final concentrations in ECSY+EPC+PLG medium.
- a 5i/L/A medium was prepared by mixing the following components (heunissen, T. W. et al. Cell Stem Cell 15, 471-487 (2014).). Concentrations shown below are final concentrations in 5i/L/A medium.
- HDM medium HDM medium was prepared by adding the following components to a 1:1 (v/v) mixed medium of DMEM/F12 medium and Neurobasal medium. The concentrations given below are the final concentrations in HDM medium. 1x N2 supplement 1x B27 supplement 1x GlutaMAX 1x Non-essential amino acids ⁇ -Mercaptoethanol 0.1 mM Penicillin-Streptomycin 0.5% bFGF (Peprotech) 20ng/mL Activin A (Peprotech) 20ng/mL CHIR99021 3 ⁇ M
- TDM medium A TDM medium was prepared by adding the following components to a 1:1 (v/v) mixed medium of DMEM/F12 medium and Neurobasal medium. The concentrations given below are the final concentrations in TDM medium.
- 0.5 ⁇ N2 supplement 0.5x B27 supplement ITS-X 0.5% 0.5x GlutaMAX 0.5 ⁇ Non-essential amino acids ⁇ -Mercaptoethanol 0.1 mM Knockout Serum Replacement (KSR, Gibco) 0.5% (v/v) FBS 0.1% BSA 50mg/mL Penicillin-Streptomycin 0.5% PD0325901 1 ⁇ M
- KSR Knockout Serum Replacement
- PD0325901 1 ⁇ M
- A83-01 0.5 ⁇ M SB590885 0.25 ⁇ M WH-4-023 0.5 ⁇ M IM-12 0.25 ⁇ M CHIR99021 1 ⁇ M SB431542 0.5 ⁇ M Recombinant human LIF 10ng/mL EGF 25ng/mL L-ascorbic
- IVC1 medium IVC1 medium was prepared by adding the following components to Advanced DMEM/F12 medium (Gibco). The concentrations given below are the final concentrations in IVC1 medium.
- IVC2 medium The following components were added to Advanced DMEM/F12 medium to prepare IVC2 medium. The concentrations given below are the final concentrations in IVC2 medium. KSR 30% (v/v) L-glutamine 2mM 1x ITS-X ⁇ -oestradiol 8nM Progesterone 200ng/mL N-acetyl-L-cysteine 25 ⁇ M Sodium lactate 0.22% (v/v) Sodium pyruvate 1mM Y27632 10 ⁇ M
- TS medium A TS medium was prepared by adding the following components to a TS basal medium. The concentrations shown below are the final concentrations of each component in TS medium.
- Y27632 (FUJIFILM Wako) 2.5 ⁇ M EGF (FUJIFILM Wako) 25ng/mL VPA (FUJI FILM Wako) 0.8 mM A83-01 (FUJIFILM Wako) 5 ⁇ M CHIR99021 (FUJIFILM Wako) 2 ⁇ M
- Endometrial epithelial cells were isolated by the following procedure. 1. Decidua were isolated manually using tweezers under a stereomicroscope. 2. The decidua were washed with wash medium (RPM 1640). 3. The decidua were transferred to a new dish and cut into 0.5-1 mm 3 with a scalpel. 4. Enzymes (dispase/collagenase) were added and allowed to react with shaking at 37° C. for 1-2 hours. 5. Medium was added to neutralize. 6. Pass through a 100 ⁇ m filter one to several times to trap cells on the filter.
- Endometrial epithelial cells were prepared by the following procedure. 1. The endometrial epithelial cells captured on the 100 ⁇ m filter in ⁇ Isolation of Endometrial Epithelial Cells> 6 were collected by inverting the 100 ⁇ m filter and washing with washing medium (RPM1640). Centrifuge at 2.500 g for 5 minutes. 3. The supernatant was discarded, 1 mL of Advanced DMEM/F-12 (Thermo Fisher Scientific) was added, and the cells were suspended by pipetting. 4. The cell suspension was transferred to a new 1.5 mL tube and centrifuged at 500 g for 5 minutes. 5.
- FIG. 3 shows a bright-field phase-contrast microscope image of the endometrium model.
- endometrial epithelial cells formed spherical structures inside Matrigel. Endometrial epithelial cells remained within the Matrigel and were not exposed on the gel surface.
- type I collagen gel the endometrial epithelial cells migrated to the surface of the gel without staying inside the type I collagen gel. Endometrial epithelial cells were exposed on the gel surface and contraction of the gel was observed.
- Example 2 An endometrium model was prepared using Matrigel or type I collagen gel by the method described above. Next, a section of the endometrium model was prepared and subjected to immunostaining with an anti-Laminin antibody and Hoechst staining. FIG. 4 shows an immunostained image of the endometrium model section.
- the endometrial epithelial cells were wrapped with Laminin and were not exposed on the gel surface.
- endometrial epithelial cells were confirmed to be exposed on the gel surface (arrow).
- Example 3 An endometrium model was prepared using type I collagen gel in the same manner as described above, except that the ECSY+EPC medium was replaced with the ECSY+EPC+PLG medium. Sections of the endometrium model were then prepared and subjected to immunostaining with anti-EpCAM antibody or anti-PGR antibody, F-actin staining with phalloidin, and Hoechst staining.
- EpCAM is an epithelial cell marker and is widely expressed in epithelial cells.
- F-actin is a structural protein of the cytoskeleton.
- PGR is a progesterone receptor and an indicator of hormone sensitivity.
- Fig. 5 shows an immunostained image of the endometrial model section.
- luminal and non-luminal structures were continuously formed.
- PGR was expressed in luminal structures, confirming their hormone sensitivity.
- the luminal structure had a similar structure to the glandular epithelium of the endometrium.
- FIG. 6 shows a phase-contrast microscope image (Phase) of endometrial cells on day 3 of planar culture and an image stained with Rhodamine B (Rhocamine B). Endometrial cells grew in colonies when plated on Matrigel. On the other hand, it was confirmed that the endometrial cells dispersed and radially migrated when cultured on a plane using type I collagen gel. These results indicated that migration of endometrial cells was promoted on the surface of type I collagen gel.
- Example 5 In order to simulate the implantation of embryonic cells into the endometrium model, a co-culture test of ES cells (transferred from Umezawa Laboratory, National Center for Child Health and Development) or TS cells and the endometrium model was conducted. . TS cells that were genetically modified to express EGFP (EGFP-TS cells) were used.
- ES cells were induced to blastocyst-like structures (blastoids) and co-cultured with an endometrium model (Yu L et al Nature 2021). Induction to blastocyst-like structures was performed as follows. Naive ES cells were seeded in 256-well microwells made of agarose at 25 to 50 cells/well. After overnight culture in 5i/L/A medium, the medium was changed to HDM medium. Three days after starting the culture in the HDM medium, the medium was changed to the TDM medium. Thereafter, the culture was continued in the HDM medium while exchanging the medium once every two days. Approximately 10 to 12 days after seeding the ES cells, the cells that formed blastocyst-like structures were collected using a mouth pipette and subjected to co-culture with the endometrium model.
- TS cells were cultured in suspension in TS medium (Okae et al Cell Stem Cell 2018) using Petri dishes for 3 days to form aggregates. This aggregate was subjected to co-culture with an endometrium model.
- An endometrium model was prepared using type I collagen gel by the above method. Then, ES cells or EGFP-TS cells were co-cultured with the endometrial model to prepare an endometrial implantation model. IVC1 medium and IVC2 medium were used for the co-culture medium. Co-cultivation was performed using IVC1 medium from the start of co-cultivation to the first day. On the second day from the start of co-cultivation, the medium was changed to IVC2 medium, and co-culture was carried out in IVC2 medium. Sections of the endometrial implantation model were prepared on the 5th day from the start of co-culture.
- OCT4 is an undifferentiated marker and is expressed in undifferentiated cells.
- SDC1 is an ST cell marker.
- FIG. 7 shows an immunostained image of a section of an implantation model using ES cells.
- FIG. 8 shows an immunostained image of a section of an implantation model using EGFP-TS cells. From FIGS. 7 and 8, it was confirmed that ES cells or EGFP-TS cells adhered to the surface of the endometrium model. For both ES cells and TS cells, the expression of SDC1 was confirmed in the cells of the implantation site in contact with the endometrium model. From this, it was considered that the cells in the implantation site were differentiated into ST cells. These results indicate that the endometrium model prepared by the above method can be used to simulate the implantation of embryonic cells.
- an endometrium model in which the apical surface of endometrial epithelial cells is exposed a method for producing the endometrium model, and an endometrium implantation model using the endometrium model are provided.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Mathematical Analysis (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Algebra (AREA)
- Computational Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Mathematical Optimization (AREA)
- Mathematical Physics (AREA)
- Pure & Applied Mathematics (AREA)
- Business, Economics & Management (AREA)
- Educational Administration (AREA)
- Educational Technology (AREA)
- Theoretical Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]間質系細胞外マトリクスを含むゲルと、子宮内膜上皮細胞と、を含み、前記子宮内膜上皮細胞の少なくとも一部が前記ゲルの表面に露出しており、前記ゲルの表面に露出する前記子宮内膜上皮細胞の少なくとも一部が、管腔構造と非管腔構造とを連続して形成している、子宮内膜モデル。
[2]前記非管腔構造が平坦な膜状構造である、[1]に記載の子宮内膜モデル。
[3]前記間質系細胞外マトリクスがI型コラーゲンである、[1]又は[2]に記載の子宮内膜モデル。
[4]前記子宮内膜上皮細胞の一部が前記ゲルの内部に存在する、[1]~[3]のいずれか1つに記載の子宮内膜モデル。
[5](a)間質系細胞外マトリクスを含むゲルの内部に、子宮内膜上皮細胞を存在させる工程と、(b)前記工程(a)後、前記子宮内膜上皮細胞を培養する工程と、を含む、子宮内膜モデルの作製方法。
[6]前記間質系細胞外マトリクスがI型コラーゲンである、[4]に記載の子宮内膜モデルの作製方法。
[7][1]~[4]のいずれか1つに記載の子宮内膜モデルと、胚細胞と、を含む、子宮内膜着床モデル。
[8]前記胚細胞が、栄養膜幹細胞、細胞性栄養膜細胞、絨毛外栄養膜細胞、合胞体性栄養膜細胞、多能性幹細胞、及びこれらから誘導される細胞からなる群より選択される少なくとも1種の細胞を含む、[7]に記載の子宮内膜着床モデル。
[9]前記胚細胞がスフェロイド又はオルガノイドを形成している、[7]又は[8]に記載の子宮内膜着床モデル。
「を含む」(comprise)という用語は、対象となる構成要素以外の構成要素を含んでいてもよいことを意味する。「からなる」(consist of)という用語は、対象となる構成要素以外の構成要素を含まないことを意味する。「から本質的になる」(consist essentially of)という用語は、対象となる構成要素以外の構成要素を特別な機能を発揮する態様(発明の効果を完全に喪失させる態様など)では含まないことを意味する。本明細書において、「を含む」(comprise)と記載する場合、「からなる」(consist of)態様、及び「から本質的になる」(consist essentially of)態様を包含する。
本開示の第1の態様は、子宮内膜モデルである。一実施形態において、子宮内膜モデルは、間質系細胞外マトリクスを含むゲルと、子宮内膜上皮細胞と、を含む。一実施形態において、前記子宮内膜上皮細胞の少なくとも一部は、前記ゲルの表面に露出している。一実施形態において、前記ゲルの表面に露出する前記子宮内膜上皮細胞の少なくとも一部は、管腔構造と非管腔構造とを連続して形成している。
子宮内膜モデル1は、培地中等で維持することができる。培地は、子宮内膜モデル1を維持可能な培地であれば、特に限定されない。培地としては、例えば、動物細胞の培養に一般的に用いられる基礎培地に、成長因子、ROCK阻害剤、GSK3β阻害剤、p38 MAPK阻害剤、成熟化誘導因子等を添加した培地が挙げられる。
基礎培地としては、例えば、Doulbecco’s modified Eagle’s Medium(DMEM)培地、DMEM/F12培地、Advanced DMEM/F12培地、IMDM培地、Medium199培地、Eagle’sMinimum Essential Medium(EMEM)培地、αMEM培地、Ham’s F12培地、RPMI1640培地、Fischer’s培地、及びこれらの混合培地等が挙げられる。好ましい基礎培地としては、例えば、DMEM/F12が挙げられる。
成長因子としては、特に限定されないが、例えば、上皮成長因子(epidermal growth factor:EGF)、線維芽細胞増殖因子(fibroblast growth factor:FGF)、骨形成タンパク質(bone morphogenetic protein:BMP)等が挙げられる。
ROCK(Rho associated coiled-coil containing protein kinase:Rho結合キナーゼ)阻害剤は、Rho結合キナーゼの機能を阻害する物質である。ROCK阻害剤としては、例えば、trans-N-(4-ピリジル)-4-(1-アミノエチル)-シクロヘキサンカルボキサミド、1-(5-イソキノリニルスルホニル)ホモピペラジン(1-(5-Isoquinolinylsulfonyl)homopiperazine)、またはこれらの塩等が挙げられる。また、例えば、Fasudil/HA1077、H-1152、およびWf-536等の低分子阻害剤、並びにそれらの誘導体等が挙げられる。ROCK阻害剤は、ROCKに対するアンチセンス核酸、siRNA、ドミナントネガティブ変異体、及びそれらの発現ベクター等であってもよい。
trans-N-(4-ピリジル)-4-(1-アミノエチル)-シクロヘキサンカルボキサミド又はその塩の市販品としては、Y27632((R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide・2HCl・H2O)等が挙げられる。ROCK阻害剤は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。
ROCK阻害剤は、Y27632を用いることが好ましい。
培地中のROCK阻害剤の濃度は、特に限定されないが、例えば、0.1~50μMとすることができ、1~20μMが好ましく、1~15μMがより好ましく、3~12μMがさらに好ましい。
GSK(Glycogen Synthase Kinase)3β阻害剤は、GSK3βの機能、例えば、キナーゼ活性(例えば、βカテニンに対するリン酸化能)を阻害する物質である。GSK3β阻害剤としては、例えば、6-[[2-[[4-(2,4-ジクロロフェニル)-5-(4-メチル-1H-イミダゾール-2-イル)-2-ピリミジニル]アミノ]エチル]アミノ]ニコチノニトリル、ケンパウロン(Kenpaullone)、1-アザケンパウロン(Azakenpaullone)、CHIR98014、AR-A014418、CT99021、CT20026、SB216763、AR-A014418、リチウム、SB415286、TDZD-8、BIO、BIO-アセトキシム、(5-メチル-1H-ピラゾール-3-イル)-(2-フェニルキナゾリン-4-イル)アミン、ピリドカルバゾール-シクロペンタジエニルルテニウム(cyclopenadienylruthenium)複合体、TDZD-8 4-ベンジル-2-メチル-1,2,4-チアジアゾリジン-3,5-ジオン、2-チオ(3-ヨードベンジル)-5-(1-ピリジル)-[1,3,4]-オキサジアゾール、OTDZT、アルファ-4-ジブロモアセトフェノン、AR-AO 144-18、3-(1-(3-ヒドロキシプロピル)-1H-ピロロ[2,3-b]ピリジン-3-イル]-4-ピラジン-2-イル-ピロール-2,5-ジオン;TWSl 19ピロロピリミジン化合物、L803 H-KEAPPAPPQSpP-NH2又はそのミリストイル化形態;2-クロロ-1-(4,5-ジブロモ-チオフェン-2-イル)-エタノン、SB216763、及びSB415286等の低分子阻害剤が挙げられる。GSK3β阻害剤は、GSK3βに対するアンチセンス核酸、siRNA、ドミナントネガティブ変異体、及びそれらの発現ベクター等であってもよい。6-[[2-[[4-(2,4-ジクロロフェニル)-5-(4-メチル-1H-イミダゾール-2-イル)-2-ピリミジニル]アミノ]エチル]アミノ]ニコチノニトリルの市販品としては、CHIR99021等が挙げられる。GSK3β阻害剤は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。
GSK3β阻害剤は、CHIR99021を用いることが好ましい。
培地中のGSK3β阻害剤の濃度は、特に限定されないが、例えば、0.1~20μMとすることができ、0.2~10μMが好ましく、0.5~5μMがより好ましく、0.5~3μMがさらに好ましい。
p38 MAPK阻害剤は、p38 MAPK(P38 mitogen-activated protein kinase)の機能を阻害する物質である。p38 MAPK阻害剤としては、例えば、SB202190(4-(4-フルオロフェニル)-2-(4-ヒドロキシフェニル)-5-(4-ピリジル)-1H-イミダゾール)、SB203580(4-[4-(4-フルオロフェニル)-2-[4-(メチルスルフィニル)フェニル]-1H-イミダゾール-5-イル]ピリジン)、VX702(6-(N-カルバモイル-2,6-ジフルオロアニリノ)-2-(2,4-ジフルオロフェニル)ピリジン-3-カルボキシアミド)、VX745(5-(2,6-ジクロロフェニル)-2-[2,4-ジフルオロフェニル)チオ]-6H-ピリミド[1,6-b]ピリダジン-6-ワン)、PD169316(4-(4-フルオロフェニル)-2-(4-ニトロフェニル)-5-(4-ピリジル)-1H-イミダゾール)、RO4402257(6-(2,4-ジフルオロフェノキシ)-2-{[3-ヒドロキシ-1-(2-ヒドロキシエチル)プロピル]アミノ}-8-メチルピリド[2,3-D]ピリミジン-7(8h)-ワン)、BIRB796(1-[5-tert-ブチル-2-(4-メチルフェニル)ピラゾール-3-イル]-3-[4-(2-モルフォリン-4-イレトキシ)ナフタレン-1-イル]ウレア)等が挙げられる。p38 MAPK阻害剤は、p38 MAPKに対するアンチセンス核酸、siRNA、ドミナントネガティブ変異体、及びそれらの発現ベクター等であってもよい。p38 MAPK阻害剤は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。
p38 MAPK阻害剤は、SB202190を用いることが好ましい。
培地中のp38 MAPK阻害剤の濃度は、特に限定されないが、例えば、0.1~20μMとすることができ、0.2~10μMが好ましく、0.5~5μMがより好ましく、0.5~3μMがさらに好ましい。
成熟化誘導因子は、子宮内膜細胞の成熟を誘導する因子である。成熟化誘導因子は、子宮内膜細胞の成熟を誘導可能な因子であれば、特に限定されない。成熟化誘導因子としては、例えば、エストロゲン受容体リガンド、プロゲステロン受容体リガンド、サイクリックAMP(cAMP)若しくはその誘導体、プロラクチン、胎盤性ラクトゲン、絨毛性ゴナドトロピン等が挙げられる。
培地中のエストロゲン受容体リガンドの濃度は、特に限定されないが、例えば、0.1~50μMとすることができ、0.5~30μMが好ましく、1~20μMがより好ましく、5~15μMがさらに好ましい。
培地中のプロゲステロン若しくはその誘導体の濃度は、特に限定されないが、例えば、0.1~20μMとすることができ、0.2~10μMが好ましく、0.5~5μMがより好ましく、0.5~3μMがさらに好ましい。
培地中のcAMP若しくはその誘導体の濃度は、特に限定されないが、例えば、0.1~200μMとすることができ、1~150μMが好ましく、10~100μMがより好ましく、20~80μMがさらに好ましい。
本開示の第2の態様は、子宮内膜モデルの作製方法である。本態様に係る方法は、(a)間質系細胞外マトリクスを含むゲルの内部に、子宮内膜上皮細胞を存在させる工程と、(b)前記子宮内膜上皮細胞を培養する工程と、を含む。
工程(a)では、間質系細胞外マトリクスを含むゲルの内部に、子宮内膜上皮細胞を存在させる。
子宮内膜上皮細胞は、子宮内膜上皮組織から単離してもよく、子宮内膜上皮細胞の培養株を用いてもよい。子宮内膜組織からの子宮内膜上皮組織からの単離方法は、公知の方法を用いることができる。子宮内膜上皮組織としては、脱落膜を用いてもよい。
子宮内膜上皮細胞は、例えば、子宮内膜上皮組織に機械的及び/又は酵素的処理を適宜使用して、細胞を分離することにより、単離することができる。機械的処理としては、メスによる切断当が挙げられる。酵素処理としては、細胞外マトリクス分解活性を有するプロテアーゼ(例えば、ディスパーゼ、コラゲナーゼ等)による処理が挙げられる。子宮内膜上皮組織の機械的及び/又は酵素的処理の後、ストレーナー又はフィルター等を用いて子宮内膜上皮細胞を回収することができる。回収した子宮内膜上皮細胞は、適宜、培地等で洗浄してもよい。
調製した子宮内膜上皮細胞は、ECSY培地等により維持することができる。
間質系細胞外マトリクスを含むゲルは、上記と同様のものを用いることができる。間質系細胞外マトリクスを含むゲルは、間質系細胞外マトリクスとしてI型コラーゲンを含むことが好ましい。
間質系細胞外マトリクスを含むゲルの内部に、子宮内膜上皮細胞を存在させる方法は特に限定されない。例えば、子宮内膜上皮細胞の培養液から遠心分離等により細胞を回収し、間質系細胞外マトリクスを含むゲルと混合してもよい。あるいは、子宮内膜上皮細胞を適切な培地に懸濁して細胞懸濁液を調製し、間質系細胞外マトリクスを含むゲルに前記細胞懸濁液を注入してもよい。
工程(b)では、前記工程(a)後、子宮内膜上皮細胞を培養する。
本開示の第3の態様は、子宮内膜着床モデルである。本態様にかかる子宮内膜着床モデルは、前記第1の態様にかかる子宮内膜モデルと、胚細胞と、を含む。
「胚細胞」とは、子宮内膜に対する着床をシミュレートし得る細胞をいう。
受精卵は、卵管内を移動して子宮内に到達する。受精卵は、卵管を移動する間に卵割し、2細胞期胚、4細胞期胚、8細胞期胚、及び桑実胚を経て、胚盤胞となる。子宮に到達した胚盤胞は、拡張胚盤胞となると透明帯が薄くなり、透明帯が破れて孵化後胚盤胞となる。孵化後胚盤胞は、子宮内膜に接して定着する。胚盤胞は、内細胞塊、胚盤胞腔、及び栄養膜から構成されており、栄養膜細胞が子宮内膜に侵襲して着床が成立する。胚細胞は、典型的には、胚を構成する細胞であり、受精卵、2細胞期胚、4細胞期胚、8細胞期胚、桑実胚、及び胚盤胞のいずれであってもよい。胚細胞は、前記のような胚から単離された細胞であってもよく、前記単離細胞から誘導された細胞であってもよい。胚細胞は、多能性幹細胞であってもよく、多能性幹細胞から誘導された細胞であってもよい。胚細胞は、胎盤から単離された細胞であってもよく、前記細胞から誘導された細胞であってもよい。
胚盤胞からのTS細胞の誘導は公知の方法により行うことができる。例えば、胎盤組織に機械的及び/又は酵素的処理を適宜使用して、細胞を分離する。その後、TS細胞に誘導する培地で細胞を培養した後、TS細胞マーカー(GATA2陽性、GATA3陽性、TFAP2陽性、ELF5陽性、ZNF750陽性、CDX2陰性等)の発現を指標として、TS細胞を樹立することができる。
CT細胞からTS細胞を誘導する方法としては、例えば、特許第6400832号に記載の方法を用いることができる。
多能性幹細胞からTS細胞を誘導する方法としては、例えば、国際公開第2020/250438号等に記載の方法等を用いることができる。
TS細胞からST細胞を誘導する方法としては、例えば、国際公開第2020/250438号等に記載の方法等が挙げられる。
TS細胞からEVT細胞を誘導する方法としては、例えば、国際公開第2020/250438号等に記載の方法等が挙げられる。
子宮内膜着床モデルは、子宮内膜モデルと、胚細胞を共培養することにより作製することができる。共培養に用いる培地は、特に限定されないが、上述の培地に加えて、実施例で用いたIVC1培地、IVC2培地等が挙げられる。
(TS basal培地)
DMEM/F12培地(FUJIFILM Wako)に、下記成分を添加してTS basal培地を作製した。下記に示す濃度は、TS basal培地中での各成分の最終濃度である。
ウシ血清アルブミン(BSA)(FUJIFILM Wako) 0.15%
ペニシリン 5,000 units/mL
ストレプトマイシン(Thermo Fisher Scientific) 5,000μg/mL
ITS-X(FUJIFILM Wako) 1%
KSR(Thermo Fisher Scientific) 1%
L-ascorbic acid(FUJIFILM Wako) 0.2mM
TS basal培地に、下記の添加因子を添加して、ECSY培地を作製した。下記に示す濃度は、ECSY培地における最終濃度である。
ヒトEGF、組換え体(FUJIFILM Wako) 50ng/mL
CHIR99021(FUJIFILM Wako) 2μM
SB202190(FUJIFILM Wako) 2μM
Y27632(FUJIFILM Wako) 10μM
ECSY培地に、下記の成熟化誘導添加因子を添加して、ECSY+EPC培地を作製した。下記に示す濃度は、ECSY+EPC培地における最終濃度である。
エストラジオール(SIGMA) 10μM
メドロキシプロゲステロン酢酸エステル(MPA)(FUJIFILM Wako) 2μM
8-Bromo-cAMP(SIGMA) 50μM
ECSY+EPC培地に、下記の成熟化誘導添加因子を添加して、ECSY+EPC+PLG培地を作製した。下記に示す濃度は、ECSY+EPC+PLG培地における最終濃度である。
ヒトプロラクチン、組換え体(Peprotech) 20ng/mL
ヒト胎盤性ラクトゲン(hPL)(R&D systems) 20ng/mL
ヒト絨毛性ゴナドトロピン(hCG)(SIGMA) 1μg/mL
下記の成分を混合して、5i/L/A培地を作製した(heunissen, T. W. et al. Cell Stem Cell 15, 471-487 (2014).)。下記に示す濃度は、5i/L/A培地における最終濃度である。
DMEM/F12培地(Invitrogen) 250mL
Neurobasal培地(Invitrogen) 250mL
N2 supplement(Invitrogen) 5mL
B27 supplement(Invitrogen) 10mL
1× GlutaMAX(Gibco)
1× Non-essential amino acids(Gibco)
β-メルカプトエタノール(Gibco) 0.1mM
Penicillin-Streptomycin(Gibco) 0.5%
ウシ血清アルブミン(BSA,Sigma) 50mg/mL
PD0325901(Stemgent) 1μM
IM-12(Enzo) 0.5μM又は1μM
SB590885(R&D systems) 0.5μM
WH-4-023(A Chemtek) 1μM
Recombinant human LIF(Peprotech) 20ng/mL
Activin A(Peprotech) 10ng/mL
1:1(v/v)のDMEM/F12培地及びNeurobasal培地の混合培地に、下記成分を添加して、HDM培地を作製した。下記に示す濃度は、HDM培地における最終濃度である。
1× N2 supplement
1× B27 supplement
1× GlutaMAX
1× Non-essential amino acids
β-メルカプトエタノール 0.1mM
Penicillin-Streptomycin 0.5%
bFGF(Peprotech) 20ng/mL
Activin A(Peprotech) 20ng/mL
CHIR99021 3μM
1:1(v/v)のDMEM/F12培地及びNeurobasal培地の混合培地に、下記成分を添加して、TDM培地を作製した。下記に示す濃度は、TDM培地における最終濃度である。
0.5× N2 supplement
0.5× B27 supplement
ITS-X 0.5%
0.5× GlutaMAX
0.5× Non-essential amino acids
β-メルカプトエタノール 0.1 mM
Knockout Serum Replacement(KSR,Gibco) 0.5%(v/v)
FBS 0.1%
BSA 50mg/mL
Penicillin-Streptomycin 0.5%
PD0325901 1μM
A83-01 0.5 μM
SB590885 0.25μM
WH-4-023 0.5μM
IM-12 0.25μM
CHIR99021 1μM
SB431542 0.5μM
Recombinant human LIF 10ng/mL
EGF 25ng/mL
L-ascorbic acid 0.75μg/mL
VPA 0.4mM
Advanced DMEM/F12培地(Gibco)に、下記成分を添加して、IVC1培地を作製した。下記に示す濃度は、IVC1培地における最終濃度である。
FBS 20%(v/v)
L-glutamine(Gibco) 2mM
1× ITS-X
β-oestradiol(Sigma) 8nM
Progesterone(Sigma) 200ng/mL
N-acetyl-L-cysteine(Sigma) 25μM
Sodium Lactate(Sigma) 0.22%(v/v)
Sodium Pyruvate(Sigma) 1mM
Y27632 10μM
Advanced DMEM/F12培地に、下記成分を添加して、IVC2培地を作製した。下記に示す濃度は、IVC2培地における最終濃度である。
KSR 30%(v/v)
L-glutamine 2mM
1× ITS-X
β-oestradiol 8nM
Progesterone 200ng/mL
N-acetyl-L-cysteine 25μM
Sodium Lactate 0.22%(v/v)
Sodium Pyruvate 1mM
Y27632 10μM
TS basal培地に、下記成分を添加してTS培地を作製した。下記に示す濃度は、TS培地中での各成分の最終濃度である。
Y27632(FUJIFILM Wako) 2.5μM
EGF(FUJIFILM Wako) 25ng/mL
VPA(FUJIFILM Wako) 0.8mM
A83-01(FUJIFILM Wako) 5μM
CHIR99021(FUJIFILM Wako) 2μM
下記手順により、子宮内膜上皮細胞を単離した。
1.実体顕微鏡下、ピンセットを用いて、手作業で脱落膜を単離した。
2.洗浄培地(RPM1640)で脱落膜を洗浄した。
3.脱落膜を新しいディッシュに移し、メスで0.5~1mm3に切断した。
4.酵素(ディスパーゼ/コラゲナーゼ)を添加し、37℃で、1~2時間、振盪しながら反応させた。
5.培地を添加して中和した。
6.100μmフィルターに1~数回通し、フィルター上に細胞を捕捉した。
下記手順により、子宮内膜上皮細胞を調製した。
1.<子宮内膜上皮細胞の単離>の6で100μmフィルターに捕捉した子宮内膜上皮細胞を、100μmフィルターを反転させて、洗浄培地(RPM1640)で洗浄することにより回収した。
2.500gで5分間遠心分離した。
3.上清を捨て、1mLのAdvanced DMEM/F-12(Thermo Fisher Scientific)を添加し、ピペッティングにより細胞を懸濁した。
4.細胞懸濁液を新しい1.5mLチューブに移し、500gで5分間、遠心分離した。
5.上清を捨て、ペレットの体積を見積もり、氷上で2~3分間タッピングした。
6.ペレット体積の約20倍容量の氷冷Matrigel(登録商標)(コーニング)を添加し、緩やかに数回ピペッティングした後、氷上に戻した。
7.37℃に予め温めたnon-treated48ウェルプレートに、20μLの細胞懸濁液を滴下した。
8.37℃で15分間以上インキュベートした。
9.250μLのECSY培地を添加して、維持した。
下記手順により、子宮内膜モデルを作製した。
1.子宮内膜オルガノイドの維持培養液から培地を除去した。
2.0.5mLのDMEM/F-12(cold)を添加し、20回ピペッティングを行って、細胞を懸濁した。
3.500gで、3分間遠心分離を行い、上清を除去した。
4.Matrigel(登録商標)(コーニング)及びI型コラーゲン(Cellmatrix(登録商標) Type I-A;新田ゼラチン)を添加した(Matrigel/I型コラーゲン=20/80(体積比))。また、コントロールには、Matrigelのみを添加した。
5.無処理48ウェルプレートに、20μLの細胞含有ゲルを滴下し、37℃で30分間インキュベートした。
6.ESCY培地を添加し、37℃、5%CO2濃度で培養した。培養中、1週間に2~3回の頻度で培地交換を行った。
7.培養7日目に、ECSY+EPC培地に交換した。
上記の方法で、Matrigel又はI型コラーゲンゲルを用いて、子宮内膜モデルを作製した。図3に、子宮内膜モデルの明視野位相差顕微鏡画像を示す。
Matrigelを用いて培養した場合、子宮内膜上皮細胞は、Matrigelの内部で球状構造を形成した。子宮内膜上皮細胞は、Matrigel内に留まり、ゲル表面に露出することはなかった。
I型コラーゲンゲルを用いて培養した場合、子宮内膜上皮細胞は、I型コラーゲンゲル内部に留まることなく、ゲル表面まで移動した。子宮内膜上皮細胞がゲル表面に露出し、ゲルの収縮が観察された。
上記の方法で、Matrigel又はI型コラーゲンゲルを用いて、子宮内膜モデルを作製した。次いで、子宮内膜モデルの切片を作製し、抗Laminin抗体による免疫染色、及びHoechst染色を行った。図4に、子宮内膜モデル切片の免疫染色画像を示す。
Matrigelを用いて培養した場合、子宮内膜上皮細胞は、Lamininで包まれており、ゲル表面に露出することはなかった。
I型コラーゲンゲルを用いて培養した場合、子宮内膜上皮細胞は、ゲル表面に露出していることが確認された(矢印)。
ECSY+EPC培地に替えてECSY+EPC+PLG培地を用いたこと以外は上記と同様の方法で、I型コラーゲンゲルを用いて、子宮内膜モデルを作製した。次いで、子宮内膜モデルの切片を作製し、抗EpCAM抗体、又は抗PGR抗体による免疫染色、ファロイジンによるF-actin染色、及びHoechst染色を行った。EpCAMは、上皮細胞マーカーであり、上皮細胞に広く発現する。F-actinは、細胞骨格の構造タンパク質である。PGRは、プロゲステロン受容体であり、ホルモン感受性の指標となる。
I型コラーゲンゲル又はMatrigelを用いて、子宮内膜細胞の平面培養を行った。図6に、平面培養3日目における子宮内膜細胞の位相差顕微鏡画像(Phase)と、Rhodamine Bによる染色画像(Rhocamine B)を示す。
Matrigelを用いて平面培養した場合、子宮内膜細胞は、コロニー状に増殖した。一方、I型コラーゲンゲルを用いて平面培養した場合、子宮内膜細胞は、分散して放射状に遊走していることが確認された。この結果から、I型コラーゲンゲルの表面では、子宮内膜細胞の遊走が促進されることが示された。
子宮内膜モデルへの胚細胞の着床をシミュレートするために、ES細胞(国立成育医療研究センター・梅澤研究室より譲渡)またはTS細胞と、子宮内膜モデルとの共培養試験を行った。TS細胞は、EGFPを発現するように遺伝子改変したTS細胞(EGFP-TS細胞)を用いた。
2 子宮内膜着床モデル
10a,10b 子宮内膜上皮細胞集合体
11 管腔構造
12 非管腔構造
20 間質系細胞外マトリクスを含むゲル
30 胚細胞
Claims (9)
- 間質系細胞外マトリクスを含むゲルと、
子宮内膜上皮細胞と、を含み、
前記子宮内膜上皮細胞の少なくとも一部が前記ゲルの表面に露出しており、
前記ゲルの表面に露出する前記子宮内膜上皮細胞の少なくとも一部が、管腔構造と非管腔構造とを連続して形成している、
子宮内膜モデル。 - 前記非管腔構造が平坦な膜状構造である、請求項1に記載の子宮内膜モデル。
- 前記間質系細胞外マトリクスがI型コラーゲンである、請求項1又は2に記載の子宮内膜モデル。
- 前記子宮内膜上皮細胞の一部が前記ゲルの内部に存在する、請求項1~3のいずれか一項に記載の子宮内膜モデル。
- (a)間質系細胞外マトリクスを含むゲルの内部に、子宮内膜上皮細胞を存在させる工程と、
(b)前記工程(a)後、前記子宮内膜上皮細胞を培養する工程と、
を含む、子宮内膜モデルの作製方法。 - 前記間質系細胞外マトリクスがI型コラーゲンである、請求項4に記載の子宮内膜モデルの作製方法。
- 請求項1~4のいずれか一項に記載の子宮内膜モデルと、
胚細胞と、
を含む、子宮内膜着床モデル。 - 前記胚細胞が、栄養膜幹細胞、細胞性栄養膜細胞、絨毛外栄養膜細胞、合胞体性栄養膜細胞、多能性幹細胞、及びこれらから誘導される細胞からなる群より選択される少なくとも1種の細胞を含む、請求項7に記載の子宮内膜着床モデル。
- 前記胚細胞がスフェロイド又はオルガノイドを形成している、請求項7又は8に記載の子宮内膜着床モデル。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21954165.3A EP4390899A1 (en) | 2021-08-18 | 2021-08-18 | Endometrium model, method for producing endometrium model, and endometrial implantation model |
PCT/JP2021/030100 WO2023021591A1 (ja) | 2021-08-18 | 2021-08-18 | 子宮内膜モデル、子宮内膜モデルの作製方法、及び子宮内膜着床モデル |
JP2023542074A JPWO2023021591A1 (ja) | 2021-08-18 | 2021-08-18 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2021/030100 WO2023021591A1 (ja) | 2021-08-18 | 2021-08-18 | 子宮内膜モデル、子宮内膜モデルの作製方法、及び子宮内膜着床モデル |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023021591A1 true WO2023021591A1 (ja) | 2023-02-23 |
Family
ID=85240218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/030100 WO2023021591A1 (ja) | 2021-08-18 | 2021-08-18 | 子宮内膜モデル、子宮内膜モデルの作製方法、及び子宮内膜着床モデル |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4390899A1 (ja) |
JP (1) | JPWO2023021591A1 (ja) |
WO (1) | WO2023021591A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116751736A (zh) * | 2023-07-18 | 2023-09-15 | 首都医科大学附属北京妇产医院 | 一种子宫内膜类器官培养基及其长期传代培养方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002142753A (ja) * | 2000-11-15 | 2002-05-21 | Bio Oriented Technol Res Advancement Inst | 動物の受精卵の共培養担体及びこの担体を用いる動物の受精卵の培養方法 |
JP2013163646A (ja) * | 2012-02-09 | 2013-08-22 | Univ Of Tokyo | 着床能改善用組成物、及びこれを含む医薬、食品または飲料 |
JP6400832B2 (ja) | 2015-03-10 | 2018-10-03 | 国立大学法人東北大学 | 胎盤を構成する細胞への分化能を有する哺乳動物の未分化前駆細胞及びその製造方法 |
JP2019505214A (ja) * | 2016-02-04 | 2019-02-28 | マサチューセッツ インスティテュート オブ テクノロジー | 統合された圧送、レベリングおよび感知を備えたモジュール式器官マイクロ生理学的システム |
JP2019198267A (ja) * | 2018-05-16 | 2019-11-21 | 国立大学法人横浜国立大学 | 細胞含有ハイドロゲル体及びその製造方法 |
JP2020130055A (ja) * | 2019-02-20 | 2020-08-31 | 学校法人東京女子医科大学 | 子宮内膜様組織及びその製造方法 |
WO2020250438A1 (ja) | 2019-06-14 | 2020-12-17 | 国立大学法人東北大学 | 胎盤を構成する細胞への分化能を有する細胞、およびその製造方法 |
-
2021
- 2021-08-18 JP JP2023542074A patent/JPWO2023021591A1/ja active Pending
- 2021-08-18 EP EP21954165.3A patent/EP4390899A1/en active Pending
- 2021-08-18 WO PCT/JP2021/030100 patent/WO2023021591A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002142753A (ja) * | 2000-11-15 | 2002-05-21 | Bio Oriented Technol Res Advancement Inst | 動物の受精卵の共培養担体及びこの担体を用いる動物の受精卵の培養方法 |
JP2013163646A (ja) * | 2012-02-09 | 2013-08-22 | Univ Of Tokyo | 着床能改善用組成物、及びこれを含む医薬、食品または飲料 |
JP6400832B2 (ja) | 2015-03-10 | 2018-10-03 | 国立大学法人東北大学 | 胎盤を構成する細胞への分化能を有する哺乳動物の未分化前駆細胞及びその製造方法 |
JP2019505214A (ja) * | 2016-02-04 | 2019-02-28 | マサチューセッツ インスティテュート オブ テクノロジー | 統合された圧送、レベリングおよび感知を備えたモジュール式器官マイクロ生理学的システム |
JP2019198267A (ja) * | 2018-05-16 | 2019-11-21 | 国立大学法人横浜国立大学 | 細胞含有ハイドロゲル体及びその製造方法 |
JP2020130055A (ja) * | 2019-02-20 | 2020-08-31 | 学校法人東京女子医科大学 | 子宮内膜様組織及びその製造方法 |
WO2020250438A1 (ja) | 2019-06-14 | 2020-12-17 | 国立大学法人東北大学 | 胎盤を構成する細胞への分化能を有する細胞、およびその製造方法 |
Non-Patent Citations (7)
Title |
---|
HAIDER, S. ET AL., STEM CELL REPORTS, vol. 11, 2018, pages 537 - 551 |
MARGHERITA Y. TURCO ET AL.: "Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium", NATURE CELL BIOLOGY, vol. 19, 2017, pages 568 - 577, XP055687061, DOI: 10.1038/ncb3516 |
MURUGANANDAN SHANMUGAM, FAN XIUJUN, DHAL SABITA, NAYAK NIHAR R.: "Development of A 3D Tissue Slice Culture Model for the Study of Human Endometrial Repair and Regeneration", BIOMOLECULES, vol. 10, no. 1, 1 January 2020 (2020-01-01), pages 1 - 14, XP093035984, DOI: 10.3390/biom10010136 * |
OKAE ET AL., CELL STEM CELL, 2018 |
T. W. ET AL., CELL STEM CELL, vol. 15, 2014, pages 471 - 487 |
YU L ET AL., NATURE, 2021 |
YU L ET AL., NATURE, vol. 591, no. 7851, March 2021 (2021-03-01), pages 620 - 626 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116751736A (zh) * | 2023-07-18 | 2023-09-15 | 首都医科大学附属北京妇产医院 | 一种子宫内膜类器官培养基及其长期传代培养方法 |
Also Published As
Publication number | Publication date |
---|---|
EP4390899A1 (en) | 2024-06-26 |
JPWO2023021591A1 (ja) | 2023-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220186189A1 (en) | Method for inducing differentiation of alveolar epithelial cells | |
US20210284968A1 (en) | Method for inducing alveolar epithelial progenitor cells | |
JP6602288B2 (ja) | 浮遊液中で内胚葉前駆細胞を培養するための方法および組成物 | |
KR102598772B1 (ko) | 상피 세포의 생체외 증식 | |
JP2022025124A (ja) | 乳房上皮幹細胞を増殖させるための培養培地 | |
JP6495830B2 (ja) | 毛様体周縁部様構造体の製造法 | |
JP2018532389A (ja) | ex vivoでの上皮細胞の増殖 | |
CN111269885A (zh) | 制备端脑或其前体组织的方法 | |
CN106536718B (zh) | 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂 | |
KR102316007B1 (ko) | 피부 유래 전구 세포의 제작 방법 | |
AU2017209742B2 (en) | Differentiation induction from human pluripotent stem cells into hypothalamic neurons | |
JPWO2020022261A1 (ja) | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 | |
JPWO2019098349A1 (ja) | 尿管芽様組織誘導方法 | |
WO2015125926A1 (ja) | 栄養膜幹細胞の樹立及び維持方法 | |
US11959100B2 (en) | Method for culture of cells | |
US20220313733A1 (en) | Method for producing renal interstitial cell | |
JP2017108705A (ja) | 心筋細胞の製造方法 | |
JP7016185B2 (ja) | 幹細胞由来涙腺組織の作製方法 | |
WO2023021591A1 (ja) | 子宮内膜モデル、子宮内膜モデルの作製方法、及び子宮内膜着床モデル | |
JP2016214138A (ja) | 栄養膜外胚葉様構造体及びその製造方法 | |
KR102183101B1 (ko) | 폐상피세포 및 대식세포를 포함하는 폐포 오가노이드 제조 방법 및 이의 용도 | |
KR20220069096A (ko) | 요관아 선단부 세포의 단리 방법 | |
RU2813532C1 (ru) | Способ очистки кардиомиоцитов | |
CA2978870C (en) | Method for inducing differentiation of alveolar epithelial cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21954165 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023542074 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021954165 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021954165 Country of ref document: EP Effective date: 20240318 |